wehewehe
He mea koʻikoʻi kā mākou mau kikowaena tofacitinib i ka hana ʻana o tofacitinib, kahi lāʻau lapaʻau kaulana i hoʻohana ʻia no ka mālama ʻana i kekahi mau ʻano o ka maʻi arthritis.He kuleana koʻikoʻi kēia waena i ka hana ʻana o tofacitinib, e hāʻawi ana i kona pono a me ka maikaʻi.Via (2R,3R) -2,3-bis [(4-methylbenzoyl)oxy]ʻakika succinic a me (3R,4R) -N,4-dimethyl-1-(phenylmethyl) - ʻO ka hui pololei o 3-piperidinamines, kā mākou hōʻoia ka huahana i ka synthesis o tofacitinib kiʻekiʻe kiʻekiʻe e hoʻokō a ʻoi aku i nā kūlana ʻoihana.
Hōʻike ka molecular formula a me ke kaumaha o kā mākou tofacitinib intermediate i kona maʻemaʻe a me kona ikaika, e lilo ia i mea hilinaʻi o ke kaʻina hana lāʻau.Me kāna mau mea i ana pono ʻia, e hōʻoiaʻiʻo kēia waena i ka kūlike a me ka pono o ka huahana hope, tofacitinib.Hāʻawi pū kāna mau mea molekala i ka paʻa holoʻokoʻa o tofacitinib a me ke ola paʻa, e hōʻoiaʻiʻo ana i ka maikaʻi a me ka hilinaʻi i ka wā lōʻihi.
E koho iā mākou
Loaʻa iā JDK nā hale hana papa mua a me nā lako hoʻokele maikaʻi, e hōʻoiaʻiʻo ana i ka lako paʻa o nā kikowaena API.Hōʻoia ka hui ʻoihana i ka R&D o ka huahana.E kūʻē i nā mea ʻelua, ke ʻimi nei mākou iā CMO & CDMO ma ka mākeke kūloko a me ka honua.